Raredr

RDR Ad Watch-Give A Fuller Life

RDR Staff
Published Online: Tuesday, Feb 21, 2017
The rare disease community knows all about being outside the box.

In an inventive new fundraising campaign by the Mended Little Hearts organization for congenial heart disease, the company has created an advertisement that becomes more colorful and interactive as the person watching the video pledges to donate more money.
 
When visiting their campaign “Give a Fuller Life”, the page features a video that opens up with a boy, Max, whose world appears lifeless, its blank, boring without any color. As the viewer taps a series of buttons on the side of the screen, pledging more money to the organization, Max’s world gets a little fuller, colorful, and joyful as he’s joined by family and friends and animals in a more vibrant world.
 
The video’s story was inspired by an actual kid named Max, who received help from Mended Little Hearts, whose mission is to “empower families affected by congenital heart disease (CHDs) through peer-to-peer support services, education, connecting families with resources, creating awareness and advocacy.”
 
This playful video shows the creative ways that organizations and advocacy groups are getting others involved in helping raise awareness and funds for rare diseases.

About Mended Little Hearts

Mended Little Hearts is non-profit, volunteer-led program providing hope and support to children, patients and families affected by congenital heart disease.  

For more information, visit http://www.mendedlittlehearts.org

About congenial heart disease

Congenial heart disease is a problem or defect with the structure of the heart, which is present at birth. The defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. They can disrupt the normal flow of blood through the heart. The blood flow can slow down, go in the wrong direction or to the wrong place, or be blocked completely.


Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$